Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pricing & policy

Ascentage wins first China reimbursement slot for lisaftoclax; olverembatinib stays listed

Both of the company's marketed leukaemia drugs will sit on China's state reimbursement list from 1 January 2027, though price and reimbursement terms were not disclosed.

16 Nov 2026 · Ascentage Pharma Group International AAPG · Company news

Ascentage Pharma said on 16 November 2026 that both of its approved blood-cancer drugs will be covered by China's state insurance reimbursement list from 1 January 2027. For lisaftoclax this is its first appearance on the list. Olverembatinib keeps the place it already held.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Ascentage Pharma Group International ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pricing & policyAll →